Highlights
2016
Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency
Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency
Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting
Biocon's Insulin Glargine Receives Regulatory Approval in Japan
Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh- Insulin in USA
Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY 17
Biocon Announces Data from Key Studies for Insulin Tregopil
2015
Biocon Introduces CIMIVIR-L™ for Hepatitis-C in India
Biocon Inaugurates World Class Devices Facility & Introduces Basalog One™ Forges Ahead on 'Make in India for the World' Mission
Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed
2014
Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb® to Treat SIRS and Cardiac Surgery Patients
Bristol-Myers Squibb and Syngene International Extend Research Collaboration
Shri Ghulam Nabi Azad Inaugurates Baxter Global Research Center at Syngene
Biocon Collaborates with Advaxis for 'ADXS-HPV'A Novel Cancer Immunotherapy
2013
Biocon Launched ALZUMAb™- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India
Biocon Enhances Partnership with Mylan through Strategic Collaboration for Insulin Products
Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis
2012
Biocon enters into an agreement with Bristol-Myers Squibb for its Insulin Tregopil drug
Biocon announced Positive Results from its Global Phase 3 study with Recombinant Human Insulin
Biocon announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine
Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoiasis
2010
Biocon announces preliminary data on its novel Insulin Tregopil drug candidate
Biocon initiates Phase 3 clinical trials in Psoriasis
2009
Biocon completes Phase 2 clinical trials in Psoriasis and Rheumatoid Arthritis.
Biocon initiates Insulin Tregopil Phase 3 study in Type 2 diabetes.
Biocon completed Phase 3 studies using Insulin Glargine and have got regulatory approval for Marketing
2008
Biocon presents data on Insulin Tregopil at the European Association for Study of Diabetes, Rome
Biocon completed Phase 2 studies using Insulin Tregopil in T2DM subjects
Biocon initiates Phase 2 studies using T1h in Psoriasis patients
Biocon completes Phase 1 clinical trial using Insulin Tregopil in NHV in Europe
Biocon initiates collaboration with Iatrica Inc. on development on novel NucleoMabs for Oncology
2007
Biocon initiates Phase 1 Clinical Trials in Europe after getting approvals from the MPA (Sweden)
Biocon initiates clinical trial of T1h in Rheumatoid Arthritis
Additional clinical trials for use of BIOMAb EGFR® in the treatment of glioma and non-small cell lung carcinoma initiated
Biocon unveils five renal therapy drugs
Biocon gets regulatory approval for GCSF
Biocon gets regulatory approval for Streptokinase
Biocon signs pact with Deakin University to jointly develop a mammalian cell bio-processing facility
2006
Biocon files PCT for novel process of manufacturing of Oral Insulin
Biocon completes phase-IV trials of INSUGEN®
Biocon launches BIOMAb-EGFR® a therapeutic monoclonal antibody-based drug for treating solid tumors of epithelial origin
2005
Biocon acquires the intellectual property of Nobex Corporation. With it, Biocon's total IP estate increases by nearly 300 patents and patent applications focused on oral peptide therapeutics in the metabolic and cardiovascular segment
Biocon and Karolinska Institute sign a MoU to collaborate in research and research education initiatives
2004
Biocon and Vaccinex partner to discover and develop therapeutic antibodies
Biocon launches INSUGEN®, the world's first recombinant human (r-DNA) insulin using a unique Pichia expression system
2003
Biocon files its 100th patent application
2002
Biocon ranks 3rd among Indian companies for filing PCT applications
Biocon files PCT application for patent on 'Methods of producing esters of Mycophenolate'
US patent office grants 3 patents on the process for the manufacture of Simvastatin
FDA approves a solid state process for the manufacture of Lovastatin
2001
US patent office grants a patent on PlaFractor™, Biocon's revolutionary bioreactor
